Genus Company Profile

What is the competitive landscape for GENUS

GENUS has thirty-four approved drugs.

There are seven US patents protecting GENUS drugs.

There are forty-five patent family members on GENUS drugs in twenty-one countries and seventeen supplementary protection certificates in six countries.

Summary for Genus

International Patents:	45
US Patents:	7
Tradenames:	27
Ingredients:	25
NDAs:	34

Drugs and US Patents for Genus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus Lifesciences	AMCINONIDE	amcinonide	CREAM;TOPICAL	076065-001	May 15, 2003	AB	RX	No	Yes
Genus	CARBINOXAMINE MALEATE	carbinoxamine maleate	TABLET;ORAL	040442-001	Mar 19, 2003	AA	RX	No	Yes
Genus	CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride	CONCENTRATE;ORAL	214542-001	Jun 2, 2021		RX	No	Yes
Genus Lifesciences	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	SOLUTION;ORAL	207108-001	Apr 22, 2020		DISCN	No	No
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-008	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,231,931		Y
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		DISCN	Yes	No	9,539,214

Expired US Patents for Genus

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	9,364,439
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	6,926,907
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	9,364,439
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	6,926,907
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	8,206,741
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	8,206,741

Paragraph IV (Patent) Challenges for GENUS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Tablets	81 mg/40 mg		2016-10-14

International Patents for Genus Drugs

Country	Patent Number	Estimated Expiration
African Regional IP Organization (ARIPO)	3628
Japan	2015051995
Morocco	33296
New Zealand	620879
Singapore	10201401695V
Ukraine	115139

Supplementary Protection Certificates for Genus Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
1534313	2015/071	Ireland		PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0809498	SPC/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
1718641	SPC/GB12/028	United Kingdom		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Genus
• Genus Lifesciences

Pharmaceutical Competitive Landscape Analysis: Genus – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Today, we'll dive deep into Genus, a unique player in the animal genetics sector, examining its market position, strengths, and strategic insights. This analysis will provide valuable information for industry professionals, investors, and anyone interested in the intersection of biotechnology and agriculture.

Genus: A Leader in Animal Genetics

Genus plc is a global leader in animal genetics, specializing in porcine and bovine genetic improvement[1]. The company's mission is to pioneer animal genetic improvement to sustainably nourish the world[10]. This unique positioning sets Genus apart in the pharmaceutical and biotechnology sectors.

Core Business and Market Reach

Genus operates through two primary brands:

1. ABS: Focused on dairy and beef cattle genetics
2. PIC: Specializing in pig genetics

The company's products and services are available in over 80 countries, demonstrating its global reach and influence[10]. Genus serves many of the Top 100 pig producers and dairies worldwide, solidifying its position as a key player in the animal genetics market[1].

Market Position and Financial Performance

Market Capitalization and Growth

As of January 15, 2025, Genus has a market capitalization of 935.43 million GBP[7]. This represents significant growth over time:

• Since January 30, 1998, Genus's market cap has increased by 2,914.56%
• The compound annual growth rate (CAGR) stands at an impressive 13.46%[7]

This growth trajectory underscores Genus's strong market position and investor confidence in its business model.

Financial Highlights

For the fiscal year 2024, Genus reported several positive financial indicators:

• Adjusted operating profit increased, with notable growth in Europe (13% increase)*
• Royalty revenue growth of 9% in Europe*[10]

These figures demonstrate Genus's ability to generate revenue and profit in competitive markets.

Genus's Competitive Advantages

Proprietary Genetic Programs

Genus has invested heavily in proprietary genetic programs, resulting in world-leading products across all its species[1]. This investment in research and development (R&D) is a key differentiator for the company.

Technological Leadership

Genus is recognized as a global leader in several cutting-edge technologies:

1. Genomics
2. Gene editing
3. Sexing technologies[1]

These technological capabilities give Genus a significant edge in the animal genetics market.

Global Supply Chain and Distribution Network

Genus's competitive advantage is further strengthened by:

• Ownership and control of proprietary lines of breeding animals
• A robust global supply chain
• An extensive technical service network
• A wide-reaching sales and distribution network[10]

This integrated approach allows Genus to maintain quality control and efficiently deliver its products to customers worldwide.

Strategic Initiatives and Future Outlook

Focus on R&D Efficiency

Genus has recently conducted a strategic review of its R&D activities, resulting in:

• Discontinuation of about one-third of R&D projects
• A more focused approach aligned with company strategy and business needs
• Expected £5m of annualized adjusted operating profit benefit from FY25[10]

This strategic realignment demonstrates Genus's commitment to efficient resource allocation and profitability.

Innovative Product Development

Genus continues to innovate, with exciting developments in the pipeline:

1. PRRSv-resistant pig: Expected FDA approval in the first half of 2024[4]
2. Sexcel Male Beef: A breakthrough using proprietary sexing technology to produce more male calves for the beef supply chain[10]

These innovations showcase Genus's ability to address industry challenges and create value-added products.

Challenges and Market Dynamics

Volatile Chinese Porcine Market

Genus faces challenges in the Chinese porcine market, including:

• Continued disease outbreaks
• A less consolidated industry structure
• Weak consumer demand[4]

Despite these challenges, Genus remains confident in PIC China's potential for medium-term growth through superior genetics and customer service.

Regulatory Landscape

As a company operating in the biotechnology sector, Genus must navigate complex regulatory environments. The company's success in obtaining approvals, such as the anticipated FDA approval for PRRSv-resistant pigs, is crucial for its growth strategy[4].

Genus's Approach to Sustainability

Genus has positioned itself as a contributor to sustainable food production. The company's technology enables customers to:

• Produce greater volumes of high-quality animal protein
• Use fewer inputs such as feed, water, and land[10]

This approach aligns with global trends towards more sustainable and efficient agricultural practices.

"Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors."[10]

Competitive Intelligence Strategies

To maintain its competitive edge, Genus likely employs several competitive intelligence strategies common in the pharmaceutical industry:

1. Data Gathering: Collecting proprietary and non-proprietary information about competitors and market trends[3]
2. Analysis: Transforming raw data into actionable insights[3]
3. Knowledge Management: Efficiently storing, organizing, and retrieving data to support decision-making[3]
4. Patent Landscape Assessment: Monitoring competitors' patent portfolios and expiration dates[6]
5. Regulatory Strategy Analysis: Understanding competitors' approaches to clinical trials, regulatory submissions, and market access[6]

These strategies allow Genus to stay ahead of industry trends and make informed decisions about product development and market expansion.

Genus in the Context of the Broader Pharmaceutical Industry

While Genus operates in a specialized niche within the pharmaceutical industry, its approach to innovation and market leadership offers valuable insights for the broader sector:

Focused Innovation

Genus's success demonstrates the value of focused innovation in niche markets. By concentrating on animal genetics, the company has become a global leader in its field.

Balancing R&D and Profitability

The company's recent R&D review showcases the importance of balancing innovation with financial performance, a challenge faced by many pharmaceutical companies.

Addressing Global Challenges

Genus's work in developing disease-resistant animals and more efficient breeding techniques aligns with broader pharmaceutical industry efforts to address global health and sustainability challenges.

Key Takeaways

1. Genus is a global leader in animal genetics, with a strong market position in both porcine and bovine sectors.
2. The company's competitive advantages include proprietary genetic programs, technological leadership, and a robust global supply chain.
3. Genus has demonstrated significant market cap growth, with a CAGR of 13.46% since 1998.
4. Strategic initiatives include focused R&D investments and innovative product development, such as PRRSv-resistant pigs.
5. The company faces challenges in volatile markets like China but remains confident in its long-term growth potential.
6. Genus's approach to sustainability aligns with global trends towards more efficient and environmentally friendly food production.
7. The company's strategies offer valuable insights for the broader pharmaceutical industry, particularly in niche market leadership and balancing innovation with profitability.

FAQs

1. What are Genus's main product lines? Genus operates through two main brands: ABS for dairy and beef cattle genetics, and PIC for pig genetics.

2. How does Genus contribute to sustainable food production? Genus's genetic technologies enable farmers to produce more high-quality animal protein while using fewer resources like feed, water, and land.

3. What is the significance of Genus's PRRSv-resistant pig? The PRRSv-resistant pig is a major innovation expected to receive FDA approval in 2024, potentially revolutionizing pig farming by increasing disease resistance.

4. How does Genus maintain its competitive edge in the market? Genus maintains its edge through proprietary genetic programs, technological leadership in areas like genomics and gene editing, and a global supply chain and distribution network.

5. What challenges does Genus face in the Chinese market? Genus faces challenges in China due to disease outbreaks, a less consolidated industry structure, and weak consumer demand. However, the company remains optimistic about long-term growth potential in this market.

Sources cited: [1] https://www.genusplc.com/about-us/our-market/ [3] https://visualping.io/blog/competitive-intelligence-in-pharma [4] https://www.businesswire.com/news/home/20230906828945/en/Genus-plc-Preliminary-Results-for-the-Year-Ended-30-June-2023 [6] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [7] https://stockanalysis.com/quote/lon/GNS/market-cap/ [10] https://www.genusplc.com/media/2151/preliminary-results-fy24-final.pdf